Chimeric Therapeutics Limited Stock: price and insider trades · Australia
Chimeric Therapeutics Limited: what insiders have been doing
Chimeric Therapeutics Limited belongs to the Health Care sector. Filings by its managers are published through ASX. In the past year (26 October 2025 to 26 October 2026), 7 filings came from 7 insiders.
The filings describe grants, exercises and other transfers rather than trades on the open market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
Insider buying of Chimeric Therapeutics Limited has been absent for the past year.
Compared with its exchange (1,596 companies, median 4 filings), a count of 7 filings is above the norm.
In the same sector, recent insider purchases at Dynavox Group AB and EssilorLuxottica also feature in our signals. This summary is built from ASX disclosures alone and does not predict where the share price will go.
Financial data
as of FY 2025FY ended June 2025 · cache
- ●Executives0ASX
- ShareASXISIN AU0000121576ASX:2924-03145117-2A1702298
- ShareASXISIN AU0000121576ASX:2924-03144433-2A1701815
- ShareASXISIN AU0000121576ASX:2924-03144430-2A1701814
- ShareASXISIN AU0000121576ASX:2924-03144429-2A1701813
- ShareASXASX:2924-03108653-2A1683093
- ShareASXISIN AU0000121576ASX:2924-03086721-2A1670070
7 of 7 declarations
About Chimeric Therapeutics Limited
Chimeric Therapeutics Limited is a biopharmaceutical company focused on developing innovative cell therapies for cancer treatment. It is listed on the Australian Securities Exchange (ASX).
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
